Ethchlorvynol

Identification

Name
Ethchlorvynol
Accession Number
DB00189
Description

Ethchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists.

Type
Small Molecule
Groups
Approved, Illicit, Withdrawn
Structure
Thumb
Weight
Average: 144.6
Monoisotopic: 144.0341926
Chemical Formula
C7H9ClO
Synonyms
  • 1-chloro-3-ethyl-1-penten-4-yn-3-ol
  • 1-Chloro-3-ethyl-pent-1-en-4-yn-3-ol
  • 3-(beta-chlorovinyl)-1-pentyn-3-ol
  • 3-(β-chlorovinyl)-1-pentyn-3-ol
  • etclorvinol
  • Ethchlorvynol
  • ethyl β-chlorovinyl ethynyl carbinol
  • β-chlorovinyl ethyl ethynyl carbinol

Pharmacology

Indication

Used for short-term hypnotic therapy in the management of insomnia for periods of up to one week in duration; however, this medication generally has been replaced by other sedative-hypnotic agents.

Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Ethchlorvynol is a sedative drug and schedule IV (USA) controlled substance. It produces cerebral depression, however the exact mechanism of action is not known.

Mechanism of action

Although the exact mechanism of action is unknown, ethchlorvynol appears to depress the central nervous system in a manner similar to that of barbiturates. Barbiturates bind at a distinct binding sites associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.

TargetActionsOrganism
AGABA(A) Receptor
positive allosteric modulator
Humans
Absorption

Rapidly absorbed from gastrointestinal tract.

Volume of distribution
Not Available
Protein binding

35-50%

Metabolism

About 90% of a dose is metabolized in the liver. Some ethchlorvynol may also be metabolized in the kidneys. Ethchlorvynol and metabolites undergo extensive enterohepatic recirculation.

Route of elimination
Not Available
Half-life

Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours.

Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

Symptoms of overdose include thrombocytopenia.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Acetazolamide.
AcetophenazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Acetophenazine.
AclidiniumEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
AgomelatineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Agomelatine.
AlfentanilThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alfentanil.
AlimemazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alimemazine.
AlmotriptanThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Almotriptan.
AlosetronThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alosetron.
AlprazolamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alprazolam.
AlverineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alverine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Avoid alcohol.
  • Take with food. Food reduces irritation.

Products

International/Other Brands
Arvynol (Pfizer) / Nostel (Dainippon) / Placidyl (Abbott) / Roeridorm (Pfizer-Roerig) / Serenesil (Abbott)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Placidyl Cap 200mgCapsuleOralAbbott1956-12-312008-06-10Canada flag
Placidyl Cap 500mgCapsuleOralAbbott1952-12-312008-06-06Canada flag
Placidyl Cap 750mgCapsuleOralAbbott1971-12-312008-06-06Canada flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more

Categories

ATC Codes
N05CM08 — Ethchlorvynol
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as ynones. These are organic compounds containing the ynone functional group, an alpha,beta unsaturated ketone group with the general structure RC#C-C(=O)R' (R' not H).
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Ynones
Alternative Parents
Tertiary alcohols / Vinyl chlorides / Chloroalkenes / Acetylides / Organochlorides / Hydrocarbon derivatives
Substituents
Acetylide / Alcohol / Aliphatic acyclic compound / Chloroalkene / Haloalkene / Hydrocarbon derivative / Organochloride / Organohalogen compound / Tertiary alcohol / Vinyl chloride
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
6EIM3851UZ
CAS number
113-18-8
InChI Key
ZEHYJZXQEQOSON-AATRIKPKSA-N
InChI
InChI=1S/C7H9ClO/c1-3-7(9,4-2)5-6-8/h1,5-6,9H,4H2,2H3/b6-5+
IUPAC Name
(1E)-1-chloro-3-ethylpent-1-en-4-yn-3-ol
SMILES
CCC(O)(\C=C\Cl)C#C

References

Synthesis Reference

Bayley, A. and McLamore, W.M.; U.S. Patent 2,746,900; May 22,1956; assigned to Chas. Pfizer & Co., Inc.

General References
Not Available
KEGG Drug
D00704
KEGG Compound
C07833
PubChem Compound
5281077
PubChem Substance
46505006
ChemSpider
4444534
RxNav
4118
ChEBI
4882
ChEMBL
CHEMBL591
Therapeutic Targets Database
DAP000163
PharmGKB
PA164746383
Drugs.com
Drugs.com Drug Page
Wikipedia
Ethchlorvynol

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
  • Banner pharmacaps inc
  • Abbott laboratories pharmaceutical products div
Packagers
Not Available
Dosage Forms
FormRouteStrength
CapsuleOral
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
boiling point (°C)28.5-30Bayley, A. and McLamore, W.M.; U.S. Patent 2,746,900; May 22,1956; assigned to Chas. Pfizer & Co., Inc.
logP1.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.143 mg/mLALOGPS
logP1.45ALOGPS
logP1.62ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)12.88ChemAxon
pKa (Strongest Basic)-3.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area20.23 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity38.64 m3·mol-1ChemAxon
Polarizability14.77 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9965
Blood Brain Barrier+0.9685
Caco-2 permeable+0.646
P-glycoprotein substrateNon-substrate0.743
P-glycoprotein inhibitor INon-inhibitor0.9023
P-glycoprotein inhibitor IINon-inhibitor0.9672
Renal organic cation transporterNon-inhibitor0.9589
CYP450 2C9 substrateNon-substrate0.7267
CYP450 2D6 substrateNon-substrate0.9
CYP450 3A4 substrateNon-substrate0.6176
CYP450 1A2 substrateNon-inhibitor0.5224
CYP450 2C9 inhibitorNon-inhibitor0.6241
CYP450 2D6 inhibitorNon-inhibitor0.9316
CYP450 2C19 inhibitorInhibitor0.5539
CYP450 3A4 inhibitorNon-inhibitor0.7814
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7382
Ames testAMES toxic0.867
CarcinogenicityCarcinogens 0.8102
BiodegradationNot ready biodegradable0.9614
Rat acute toxicity2.7881 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9406
hERG inhibition (predictor II)Non-inhibitor0.9289
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Kind
Protein group
Organism
Humans
Pharmacological action
Yes
Actions
Positive allosteric modulator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...

Components:
References
  1. Smeyatsky N, Baldwin D, Botros W, Gura R, Kurian T, Lambert MT, Patel AG, Steinert J, Priest RG: The treatment of sleep disorders. S Afr Med J. 1992 May 2;Suppl:1-8. [PubMed:1585214]
  2. ChEMBL Compound Report Card [Link]

Drug created on June 13, 2005 07:24 / Updated on September 03, 2020 19:01

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates